ArticleJournal of gastrointestinal oncology2019
Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome.
Article in Journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data.BMJ neurology open · 2024Review
- Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.Current neurology and neuroscience reports · 2023Review
- Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma.Oxford medical case reports · 2022Article
- Pathological complete response to pembrolizumab in patients with metastatic ascending colon cancer with microsatellite instability.Clinical journal of gastroenterology · 2022Article
- High expression ofJournal of gastrointestinal oncology · 2021Article
- Complete closure of a colo-duodenal fistula in a patient with advanced ascending colon cancer after pembrolizumab combined with radiation therapy: a case report.Surgical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, clinical trials with programmed death-1 (PD-1) inhibitors exclude patients with preexisting autoimmune disorders such as Guillain-Barre syndrome (GBS). Therefore, the scientific literature has limited information about the efficacy and safety of PD-1 inhibitors in cancer patients with autoimmune disorders. Immune checkpoint inhibitors can exacerbate preexisting autoimmune disorders and can induce severe immune-related adverse events. Here, we report the case of a 73-year-old female patient with history of GBS and mismatch repair deficient metastatic colorectal cancer who achieved a durable complete response to pembrolizumab. The patient was maintained on intravenous immunoglobulin (IVIG) during her treatment without any neurological exacerbations. This case highlights the feasibility of PD-1 inhibitors in select patients with neurological autoimmune disorders and calls for more systematic evaluation of checkpoint inhibitors in patients with cancer and GBS, especially with the known link between this disorder and malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.